Tony Ho, M.D.

Dr. Tony Ho has 20-years of comprehensive R&D experience in the biotechnology and pharmaceutical industry. His most recent role was as the Executive Vice President, Research and Development at CRISPR Therapeutics, where he spearheaded R&D initiatives spanning the entire spectrum of development phases, encompassing discovery, early and late-stage clinical development, and regulatory affairs. Notably, Dr. Ho played a pivotal role in the creation of the groundbreaking CRISPR-based therapy known as Casgevy, a pioneering achievement in the field. Dr. Ho has held several roles of increasing seniority at AstraZeneca, most recently serving as the Senior Vice President and Head of Oncology Integration and Innovation. At AstraZeneca, he led the development and commercialization of two key drugs: LYNPARZA, a PARP inhibitor for ovarian cancer, IMFINZI, a PD-L1 inhibitor AstraZeneca’s first immuno-oncology drug for bladder cancer and IMJUDO, a anti-CTLA4 for lung cancer. Before that, Dr. Ho was the Neurology and Ophthalmology Clinical Section Head at Merck Research Laboratories, Merck & Co., and led multiple development programs, including the approval of Maxalt for pediatric migraine and Zioptan for glaucoma. Previously, he was the Co- Founder and Chief Scientific Officer of Neuronyx, a regenerative medicine company.

Dr. Ho is also an adjunct Associate Professor at both the University of Pennsylvania and Johns Hopkins University. He earned his M.D. from the Johns Hopkins University School of Medicine and his B.S. in Electrical Engineering at the University of California, Los Angeles.